Aktuellt
SENASTE
Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy, compared to chemotherapy alone, in triple negative breast cancer. The initial efficacy results are anticipated from mid-2025, potentially representing a near-term catalyst for the company.
LÄS MER
